# MAGNETISMM-32 (NCT06152575)

> MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06152575
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab; Elotuzumab; Pomalidomide; Dexamethasone; Bortezomib; Carfilzomib
- Enrollment: 492
- Primary outcome: Progression free survival per International Myeloma Working Group criteria

## Indexed commentary on MAGNETISMM-32 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=magnetismm-32-nct06152575